mrepo:46draft

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision		 Previous revision
Last revisionBoth sides next revision
mrepo:46draft [05/12/2019 @ 15:56] – [Insight 46] adammooremrepo:46draft [10/12/2019 @ 08:39] – adammoore
Line 3: Line 3:
 ---- ----
    
-Insight 46 is a neuroscience sub-study of the NSHD. Launched in 2015, Insight 46 recruited 502 study members selected at random from those who attended a clinical visit at 60–64 years and on whom relevant life course data are available. The study aims to investigate how life course factors and genetics influence the development of brain pathologies and impact on cognition, and so to provide insights into healthy brain ageing and the development of dementia.  +Insight 46 is a neuroscience sub-study of the NSHD. Launched in 2015, Insight 46 recruited 502 study members selected at random from those who attended a clinical visit at 60–64 years and on whom relevant life course data are available. The study aims to investigate how life course factors and genetics influence the development of brain pathologies and impact on cognition, to provide insights into healthy brain ageing and the development of dementia.  
  
-For Insight 46, participants attended two clinic visits, two years apart. Each visit consists of a combination of brain imaging, biosampling and clinical interview, including:+For Insight 46, participants attended two clinic visits, two years apart. Each visit consists of a combination of brain imaging, biosampling and a clinical interview, including:
    
   * Multi-modal MR imaging with concurrent acquisition of b-amyloid PET scanning.   * Multi-modal MR imaging with concurrent acquisition of b-amyloid PET scanning.
Line 24: Line 24:
 === Accessing Insight 46 data === === Accessing Insight 46 data ===
 ---- ----
-Much of the Insight 46 data collected at the first wave of clinic visits is available via [[skylark:skylark|Skylark]], and access to these data can be [[nshd:forms | requested]] in the same way as for other NSHD variables. \\ \\ The Insight 46 datasets currently include, but are not limited to:+Much of the Insight 46 data collected at the first wave of clinic visits is available via [[skylark:skylark|Skylark]], and access to these data can be [[nshd:forms | requested]] in the same way as for the other NSHD variables. \\ \\ The Insight 46 datasets currently include, but are not limited to:
    
   * {{apoe.pdf|ApoE status }}   * {{apoe.pdf|ApoE status }}
Line 33: Line 33:
   *  {{Medication.pdf|Medication}} usage   *  {{Medication.pdf|Medication}} usage
   *  Cognitive test results - including {{ad8.pdf|ad8}}, {{mci.pdf|mci}}, {{scd_mycog.pdf|scd and MyCog}}, {{mmse.pdf|mmse}} and others    *  Cognitive test results - including {{ad8.pdf|ad8}}, {{mci.pdf|mci}}, {{scd_mycog.pdf|scd and MyCog}}, {{mmse.pdf|mmse}} and others 
-  *  {{Audiometry.pdf|Audiometry}}+  *  {{Audiometry.pdf|Audiometry}}  
 \\ \\  \\ \\ 
 ---- ----
-Insight 46 was funded by Alzheimer’s Research UK, MRC Dementias Platform UK, The Wolfson Foundation, Weston Brain Institute, Brain Research UK, and British Heart Foundation. The 18F Florbetapir amyloid PET tracer was provided by AVID Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly+Insight 46 was funded by Alzheimer’s Research UK, MRC Dementias Platform UK, The Wolfson Foundation, Weston Brain Institute, Brain Research UK, and British Heart Foundation. The 18F Florbetapir amyloid PET tracer was provided by AVID Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.